Improving positive and negative symptoms with dopamine D2 partial agonists

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

  1. Stahl SM. CNS Spectr 2017; 22: 375-384
  2. Stahl SM. 4th Edition, New York. NY. Cambridge University Press 2013
  3. Lacroix LP et al. Neuropsychopharmacology 2003;28:839-49
  4. Leggio GM et al. Neuropsychopharmacology 2008;18: 271-277
  5. Stahl SM. Actra Psychiatr Scand 2020; 10.1111:acps.13266
  6. Citrome L et al. CNS Spectre 2018: 23: 228-38
  7. Pillinger T et al. Lancet Psychiatry 2020: 7: 64-77
  8. Huhn M et al. Lancet 2018: 394: 939-951
  9. Abbas A and Roth BL. Expert Opin Pharmacotherapy 2008; 9: 3251-3259 
  10. Correll. J Clin Psychiatry 2019; 80: 18m12495
  11. Németh GY. Lancet 2017: 389: 1103-1113
Du lämnar Progress in Mind Sverige
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
Den här informationen är endast avsedd för hälso- och sjukvårdspersonal
Register for access to Progress in Mind in your country